Back
Ultragenyx Pharmaceutical 10K Form
Sell
46
RARE
Ultragenyx Pharmaceutical
Last Price:
52.02
Seasonality Move:
11.62%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-03 | 10Q | RARE/Ultragenyx Pharmaceutical Quarterly |
| 2023-11-03 | 10Q | RARE/Ultragenyx Pharmaceutical Quarterly |
| 2023-08-04 | 10Q | RARE/Ultragenyx Pharmaceutical Quarterly |
| 2023-05-05 | 10Q | RARE/Ultragenyx Pharmaceutical Quarterly |
| 2022-11-03 | 10Q | RARE/Ultragenyx Pharmaceutical Quarterly |
| 2022-07-29 | 10Q | RARE/Ultragenyx Pharmaceutical Quarterly |
Receive RARE News And Ratings
See the #1 stock for the next 7 days that we like better than RARE
RARE Financial Statistics
Sales & Book Value
| Annual Sales: | $434.25M |
|---|---|
| Cash Flow: | $-81.47M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $4.69 |
| Price / Book: | 11.25 |
Profitability
| EPS (TTM): | -7.30000 |
|---|---|
| Net Income (TTM): | $-585.12M |
| Gross Margin: | $389.04M |
| Return on Equity: | -290% |
| Return on Assets: | -42% |
Ultragenyx Pharmaceutical Earnings Forecast
Key Ultragenyx Pharmaceutical Financial Ratios
- The Gross Profit Margin over the past 19 years for RARE is 89.59%.
- The Selling, General & Administrative Expenses for RARE have been equal to 71.34% of Gross Profit Margin.
- The Research & Development expenses have been 149.33% of Revenue.
- The Interest Expense is -10.88% of Operating Income.
- The Net Earning history of RARE is -139.70% of Total Revenues.
- Per Share Earnings over the last 20 years have been positive in 8 years.
Ultragenyx Pharmaceutical Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | RARE |
| CUSIP: | 90400D |
| Website: | ultragenyx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 3.54 |
| Quick Ratio: | 3.19 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
RARE Technical Analysis vs Fundamental Analysis
Sell
46
Ultragenyx Pharmaceutical (RARE)
is a Sell
Is Ultragenyx Pharmaceutical a Buy or a Sell?
-
Ultragenyx Pharmaceutical stock is rated a Sell
The current Ultragenyx Pharmaceutical [RARE] share price is $52.80. The Score for RARE is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.